Show simple item record

dc.contributor.authorColeman, N
dc.contributor.authorBridges, L
dc.contributor.authorSaran, F
dc.date.accessioned2018-02-15T12:19:56Z
dc.date.issued2017-07
dc.identifier.citationJournal of neuro-oncology, 2017, 133 (3), pp. 667 - 668
dc.identifier.issn0167-594X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1105
dc.identifier.eissn1573-7373
dc.identifier.doi10.1007/s11060-017-2483-z
dc.formatPrint-Electronic
dc.format.extent667 - 668
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectBrain Neoplasms
dc.subjectMultiple Sclerosis
dc.subjectDNA Repair Enzymes
dc.subjectDNA Modification Methylases
dc.subjectTumor Suppressor Proteins
dc.subjectDNA Methylation
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectRandomized Controlled Trials as Topic
dc.titleMGMT promoter methylation status: time for a frank discussion.
dc.typeJournal Article
dcterms.dateAccepted2017-05-15
rioxxterms.versionofrecord10.1007/s11060-017-2483-z
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of neuro-oncology
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume133en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorSaran, Franken
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record